Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report)‘s stock had its “sell (e)” rating reissued by stock analysts at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.
Bluejay Diagnostics Price Performance
BJDX opened at $3.34 on Tuesday. The company’s 50-day moving average is $1.66 and its 200 day moving average is $1.84. Bluejay Diagnostics has a fifty-two week low of $1.26 and a fifty-two week high of $12.45. The firm has a market capitalization of $4.98 million, a P/E ratio of -0.03 and a beta of 0.54.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.41) earnings per share for the quarter.
Bluejay Diagnostics Company Profile
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Read More
- Five stocks we like better than Bluejay Diagnostics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Invest in the FAANG Stocks
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Options Trading – Understanding Strike Price
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
